- Investing Ideas
- /
- Japanese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Japanese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Takara Bio
Market Cap: JP¥114.6b
Engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally.
4974
JP¥952.00
7D
1.5%
1Y
-9.3%
Chugai Pharmaceutical
Market Cap: JP¥11.2t
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
4519
JP¥6,827.00
7D
3.4%
1Y
-2.2%